We evaluated the distribution and risk of disease progression (PD) in first-line therapy of unresected metastatic colorectal cancer (mCRC) patients receiving chemotherapy + biologics. The aim of the analysis is to provide guidance for the timing of disease reassessments during first-line therapy.
Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO☆
Annals of Oncology | | M.M. Germani, V. Heinemann, D. Rossini, L. Fischer von Weikersthal, F. Pietrantonio, K. Heinrich, A. Stahler, S. Lonardi, F. Kaiser, T. Decker, L. Salvatore, L. Weiss, F. Morano, M. Fuchs, F. Bergamo, C. Antoniotti, G. Masi, S. Stintzing, P. Frumento, C. Cremolini, D.P. Modest
Topics: colorectal-cancer, chemotherapy